Arcus Biosciences

Creating Innovative Cancer Immunotherapies

Learn more about us

Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.

Learn more

Pipeline

AB928

AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.

AB154

AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.

AB122

AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.

AB680

AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.

Go to Pipeline

Arcus has approximately 75 employees with significant expertise in immunology, medicinal chemistry, biochemistry, enzymology, pharmacology, and structural biology.

Meet Our Leadership